StocksDeepDive
Snapshot · Foreign US-listed · generated 2026-11-11 20:45 UTC

AZN — AstraZeneca PLC

EXPENSIVE (MOS -5.5%) · Quality 72/100

Price
185.1
Intrinsic value
175.48
Margin of safety
-5.5%
Implied growth (reverse DCF)
+8.9%
model assumes +8.0%
Value Score
25.2
Quality
72
Psychology
-18.2
Discovery
5.6
price/volume attention only
Moat score
66.2
erosion: none

Value Score: bottom 34% of Foreign US-listed · Quality: top 27%

Dividend: 2.153/share (TTM) · yield 1.2% · payout 30%

Open the interactive Deep Dive for AZN →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/AZN - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is AZN undervalued?

As of 2026-11-11, AZN trades at 185.1 against a computed intrinsic value of 175.48 (-5.5% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is AstraZeneca PLC's Value Score?

AstraZeneca PLC's Value Score is 25.2 as of 2026-11-11 - it combines value, quality, crowd psychology and market attention into one number.

Does AZN pay a dividend?

Yes - AZN's trailing twelve-month dividend is 2.153/share, a yield of 1.2% at the current price (as of 2026-11-11).